The new pharmacotherapy of schizophrenia
Author(s)
Bibliographic Information
The new pharmacotherapy of schizophrenia
（Clinical practice series, no. 36）
American Psychiatric Press, c1996
Available at / 4 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Schizophrenia is a severe and complicated illness that has challenged researchers for years. Only recently, the first significant gains in the treatment of schizophrenia in more than 40 years have been made. The New Pharmacotherapy of Schizophrenia equips both the clinician and researcher with new information for the improved treatment of schizophrenia. In this practical clinical guide, 19 distinguished contributors synthesize recent advances and update new developments in the treatment of schizophrenia. The emergent era in the pharmacotherapy of schizophrenia is characterized by a new class of antipsychotic agents that promise superior efficacy and more favorable side-effect profiles. One of the most promising drugs, clozapine, is discussed in the book in terms of its current status and clinical applications. Risperidone's wide use as a first-line antipsychotic agent is considered. Clinical aspects and mechanisms of action of new and experimental antipsychotic agents are explored, and the current status of the traditional neuroleptic agents is reviewed. New information has also led to an improved understanding of how to employ existing pharmacotherapeutic agents.
Approaches to augmenting traditional neuroleptic drug efficacy through the use of "add-on" agents is considered. Treatment strategies developed specifically for two common and debilitating symptom clusters in schizophrenia, negative symptoms and depression, are also presented.
Table of Contents
Introduction and overview. Clozapine: current status and clinical applications. Risperidone: clinical applications. Future antipsychotic agents: clinical implications. New neuroleptics and experimental antipsychotics: future roles. Conventional neuroleptic treatment: current status, future role. Augmenting antipsychotic efficacy: new approaches. Noradrenergic systems: a target for augmenting pharmacotherapy. Benzodiazepines. Treating negative symptoms: pharmacological strategies. Treatment of depression in patients with schizophrenia. Conclusion. Index.
by "Nielsen BookData"